Xavier Pivot

Pivot was appointed as the Director General of the Paul-Strauss Center and the Strasbourg Cancer Institute in 2017.

In 2016, he was appointed as the President of the Monegasque Biennial of Cancerology.

Pivot's study represented the largest French academic study in breast cancer, carried out with 3,484 patients with HER2-overexpressing breast cancer. Pivot was also involved in the late 2010s in the creation of trastuzumab biosimilars, the aim of which is to offer identical efficacy at a lower cost. He was the scientific coordinator and principal investigator of the first trastuzumab biosimilar registered worldwide in 2017, Samsung BioEpis SB3.

Pivot joined the University Hospital of Besançon in 2001 as a university professor and head of the medical oncology department.

He graduated with a medical degree from the University of Nice in 1994 and received his PhD in Pharmacology from the University of Marseille in 1998.

Pivot's focus lies in the research of anti-cancer drugs. Since the late 1990s, his main scientific interest has been centered on a therapeutic antibody, trastuzumab, and the HER2 (ERBB2)-positive breast cancer. He has worked on alternatives like lapatinib and on optimizing the use of trastuzumab. He participated in the development of a subcutaneous form that allows for easier administration.

Xavier Pivot (born April 20, 1967) is a French oncologist, university professor, breast cancer specialist and general director of the Strasbourg Cancer Institute.⁣⁣ He is best known for his research on treatments with trastuzumab in HER2-positive breast cancers.

Pivot was born on April 20, 1967, in Draguignan, France.